Neogenomics (NEO) Revenue (2010 - 2026)

Neogenomics (NEO) has reported Revenue for 17 consecutive years, with $186.7 million the latest figure, recorded in Q1 2026.

• Revenue for Q1 2026 came in at $186.7 million, up 11.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $746.0 million (up 10.95% YoY), and the FY2025 annual result was $727.3 million, up 10.11% from the prior year.
• Revenue was $186.7 million for Q1 2026 at Neogenomics, down from $190.2 million in the prior quarter.
• Over five years, Revenue peaked at $190.2 million in Q4 2025 and troughed at $117.2 million in Q1 2022.
• Average Revenue over 5 years is $157.4 million, with a median of $156.2 million recorded in 2024.
• Year-over-year, Revenue gained 1.42% in 2022 and gained 17.99% in 2023.
• Over 5 years, Revenue stood at $138.7 million in 2022, then rose by 12.15% to $155.6 million in 2023, then gained by 10.57% to $172.0 million in 2024, then grew by 10.56% to $190.2 million in 2025, then dropped by 1.84% to $186.7 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $186.7 million in Q1 2026, $190.2 million in Q4 2025, and $187.8 million in Q3 2025.